---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-007190"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:18:31.435926+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M

## Summary
- Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.
- Net income $18.6M for three months ended Dec 31, 2025.
- Growth driven by lisdexamfetamine and naltrexone product launches after prior year comparable period.
- Conference call Feb 18, 2026 at 11:30 AM EST; questions due by Feb 17 evening.

## SEC filing metadata
- accession: 0001493152-26-007190
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/0001493152-26-007190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315226007190/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-007190
- JSON: https://secwatch.observer/filing/0001493152-26-007190.json
- Plain text: https://secwatch.observer/filing/0001493152-26-007190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.